Abstract 570P
Background
Osimertinib is the standard of care for the first-line treatment of advanced NSCLC (aNSCLC) patients (pts) with epidermal growth factor receptor (EGFR) activating mutations. Limited Chinese patients’ data in real-world setting are available regarding the effectiveness of osimertinib in EGFRm aNSCLC, especially in patients harboring uncommon EGFR mutations.
Methods
Patients treated with first-line osimertinib were retrospectively collected from 11 hospitals in China between March 25, 2017 and December 31, 2022. Mutations were categorized as EGFR activating mutations (19del/21L858R; cohort 1) and uncommon mutations (G719X, L861Q, S768I, 20ins, de novo T790M; cohort 2). Patient characteristics, progression-free survival (PFS), time to progression (TTP), objective response rate (ORR), and disease control rate (DCR) were analyzed.
Results
A total of 385 patients with stage IV NSCLC were included, 308 pts in cohort 1 and 77 pts in cohort 2. The median age was 59 years, 214 (55.6%) were female, 350 (90.9%) were adenocarcinoma, and 141 (36.6%) patients had documented brain metastases (35 patients received whole-brain radiotherapy). In cohort 1, the median follow-up was 32.8 months and mPFS was 20.8 months (19del subgroup: 22.7 months; 21L858R subgroup: 14.8 months). For patients with/without documented brain metastases, mPFS was 15.6 months and 23.4 months, respectively. mTTP was 21.5 months for all patients. ORR was 75.6%, including 3 patients with CR and 230 patients with PR. DCR was 94.2%. In cohort 2, ORR was 64.9% (50 patients with SD) and DCR was 93.5%. with a median follow-up of 8.3 months, both mPFS and mTTP were 7.3 months. No new safety signals were observed. Table: 570P
| Cohort 1 (19del, 21L858R) | Cohort 2 (G719X, L861Q, S768I, 20ins, de novo T790M) | |
| n (%) | 308 (80%) | 77 (20%) |
| CRPRSDPD | 3 (0.9%)230 (74.7%)57 (18.5%)18 (5.9%) | 0 (0%)50 (64.9%)22 (28.6%)5 (6.5%) |
| ORR (%) | 75.6% | 64.9% |
| DCR (%) | 94.2% | 93.5% |
| mPFS (month) | 20.8m | 7.3m |
| mTTP(month) | 21.5m | 7.3m |
Conclusions
The result is consistent with FLAURA study for patients with EGFR-activating mutation. Osimeritinib showed clinical activity in patients with EGFR uncommon mutations as first-line treatment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
549P - Drug-induced interstitial lung disease in patients with non-small cell lung cancer treated with immunotherapy for postoperative recurrence: Evaluation of CT findings and histopathological findings of the background lung
Presenter: shodai fujimoto
Session: Poster Display
Resources:
Abstract
551P - Real-world incidence and outcomes of immune-related adverse events in NSCLC patients
Presenter: Andrea Knox
Session: Poster Display
Resources:
Abstract
552P - TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in Asian patients (pts) with previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs)
Presenter: Yasushi Goto
Session: Poster Display
Resources:
Abstract
553P - Preceding plasma EGFR vs upfront tissue NGS for advanced NSCLC in the Chinese population: A single centre experience in Hong Kong
Presenter: Janet Du
Session: Poster Display
Resources:
Abstract
554P - Comparison of the analytical performance of endobronchial ultrasound-guided transbronchial needle aspiration and other sampling methods for the Oncomine Dx target test: An observational study
Presenter: Kazuhito Miyazaki
Session: Poster Display
Resources:
Abstract
555P - Quality of life in patients with stage IV non-small cell lung cancer and the influence of druggable mutations over time: A prospective, territory-wide study in Hong Kong
Presenter: Jason C S Ho
Session: Poster Display
Resources:
Abstract
556P - Results from the phase I study on efficacy and safety of iruplinalkib (WX-0593) for anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) patients who received prior second-generation ALK tyrosine kinase inhibitors (TKIs)
Presenter: xuezhi Hao
Session: Poster Display
Resources:
Abstract
557P - Longitudinal plasma proteomic profiling of EML4-ALK positive lung cancer receiving ALK-TKIs therapy
Presenter: Shasha Wang
Session: Poster Display
Resources:
Abstract
558P - Treatment duration and adherence of brigatinib as second-line treatment after crizotinib for ALK+ NSCLC in South Korea
Presenter: Jeong Eun Lee
Session: Poster Display
Resources:
Abstract
559P - Comprehensive survey of AACR GENIE database revealed a wide range of TMB distribution among all three classes (I, II, III) of BRAF mutated NSCLC
Presenter: Zhaohui Arter
Session: Poster Display
Resources:
Abstract